Shareholders Approve Massive Dilution, Change of Control, and Expanded Equity Plans

summarizeSummary

Sensei Biotherapeutics shareholders approved a massive increase in authorized shares, the conversion of Series B Preferred Stock resulting in over 20% dilution and a change of control, and new, highly dilutive equity compensation plans.

check_boxKey Events · Financing and Capital Events · SNSE

• Authorized Shares Increased by 24x

  Stockholders approved an amendment to increase the authorized number of common stock from 12,500,000 to 300,000,000 shares, providing immense capacity for future equity issuance.

• Series B Preferred Stock Conversion Approved

  Shareholders approved the issuance of common stock upon conversion of Series B Non-Voting Convertible Preferred Stock, which will represent more than 20% of outstanding common stock and result in a change of control. This finalizes a major dilutive financing event tied to the recent acquisition.

• New Equity Incentive Plan Approved

  The 2026 Equity Incentive Plan was approved with an initial reserve of 2,671,981 shares, plus up to 311,164 returning shares from a prior plan, and an automatic annual increase of 5% of outstanding shares.

• New Employee Stock Purchase Plan Approved

  The 2026 Employee Stock Purchase Plan was approved with an initial reserve of 267,198 shares and an automatic annual increase of up to 1% of outstanding shares.

auto_awesomeAnalysis · SNSE · Life Sciences

Shareholders have approved several critical proposals, including a substantial increase in authorized common stock from 12.5 million to 300 million shares, providing significant headroom for future dilutive capital raises. Crucially, the approval of the Series B Preferred Stock conversion finalizes a major financing and acquisition, explicitly leading to over 20% dilution for existing shareholders and a change of control. Additionally, new equity incentive and employee stock purchase plans were approved with initial share reserves representing over 200% of current outstanding shares, plus annual evergreen provisions, indicating substantial future dilution for compensation.